Experimental Endotoxemia Induces Adipose Inflammation and Insulin Resistance in Humans
- Nehal N. Mehta1,2,3,
- Fiona C. McGillicuddy1,2,
- Paul D. Anderson4,
- Christine C. Hinkle1,2,
- Rachana Shah3,
- Leticia Pruscino1,2,
- Jennifer Tabita-Martinez1,
- Kim F. Sellers5,
- Michael R. Rickels2,3 and
- Muredach P. Reilly1,2,3
- 1the Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania;
- 2the Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania;
- 3Institute for Diabetes Obesity and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania;
- 4Department of Medicine, Darthmouth Hitchcock Medical Center, Lebanon, New Hampshire;
- 5Department of Biostatistics, Georgetown University Medical School, Washington, D.C.
- Corresponding author: Muredach P. Reilly, muredach{at}spirit.gcrc.upenn.edu.
Abstract
OBJECTIVE An emerging model of metabolic syndrome and type 2 diabetes is of adipose dysfunction with leukocyte recruitment into adipose leading to chronic inflammation and insulin resistance (IR). This study sought to explore potential mechanisms of inflammatory-induced IR in humans with a focus on adipose tissue.
RESEARCH DESIGN AND METHODS We performed a 60-h endotoxemia protocol (3 ng/kg intravenous bolus) in healthy adults (n = 20, 50% male, 80% Caucasian, aged 27.3 ± 4.8 years). Before and after endotoxin, whole-blood sampling, subcutaneous adipose biopsies, and frequently sampled intravenous glucose tolerance (FSIGT) testing were performed. The primary outcome was the FSIGT insulin sensitivity index (Si). Secondary measures included inflammatory and metabolic markers and whole-blood and adipose mRNA and protein expression.
RESULTS Endotoxemia induced systemic IR as demonstrated by a 35% decrease in Si (3.17 ± 1.66 to 2.06 ± 0.73 × 10−4 [μU · ml−1 · min−1], P < 0.005), while there was no effect on pancreatic β-cell function. In adipose, endotoxemia suppressed insulin receptor substrate-1 and markedly induced suppressor of cytokine signaling proteins (1 and 3) coincident with local activation of innate (interleukin-6, tumor necrosis factor) and adaptive (monocyte chemoattractant protein-1 and CXCL10 chemokines) inflammation. These changes are known to attenuate insulin receptor signaling in model systems.
CONCLUSIONS We demonstrate, for the first time in humans, that acute inflammation induces systemic IR following modulation of specific adipose inflammatory and insulin signaling pathways. It also provides a rationale for focused mechanistic studies and a model for human proof-of-concept trials of novel therapeutics targeting adipose inflammation in IR and related consequences in humans.
Footnotes
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Received March 10, 2009.
- Accepted September 3, 2009.
- © 2010 American Diabetes Association











